Forget Betting Everything on Tesla’s Robot. This Fund Already Owns the Robotics Winners

The post Forget Betting Everything on Tesla’s Robot. This Fund Already Owns the Robotics Winners appeared first on 24/7 Wall St..

Owning Tesla (NASDAQ:TSLA) for the robotics story is now the dominant retail thesis: bulls argue Optimus and the Cybercab are option value the market has not paid for, and that the auto business is almost a free call on humanoid robots. The case has logic. Tesla is installing first-generation Optimus production lines at Fremont and a second-generation line at Gigafactory Texas, both designed to produce 10 million robots a year. The problem is structural. For a reader who wants exposure to robotics rather than a Tesla position, the Global X Robotics & Artificial Intelligence ETF (NASDAQ:BOTZ) already holds companies that ship robots and the chips that train them.

Why the Tesla robotics bet is expensive

Tesla trades at a trailing P/E of 371 with a $1.43 trillion market cap. Optimus revenue today is effectively zero. The upside in robotics is priced into a multiple that already assumes execution. Q1 FY26 was a solid auto quarter, with revenue of $22.39 billion, up 15.78% year over year, and non-GAAP EPS of $0.41. However, the auto gross margin of 21.1% funds the robot program, but does not justify the multiple.

Prediction markets are skeptical of the near-term catalysts that would close the gap. Polymarket assigns a 13.5% probability to an Optimus release by year-end 2026 and a 2.8% probability to a California robotaxi launch by June 30. That means concentrated key-person, regulatory, and execution risk in a single stock that has already declined 15.14% year-to-date.

What BOTZ actually owns

That basket maps to existing robotics revenue. NVIDIA (NASDAQ:NVDA) reported Q1 FY27 revenue of $81.62 billion, up 85.23% year over year, with Data Center revenue at $75.25 billion, up 92%. That is the compute backbone for every robotics program, including Tesla’s own Optimus training. ABB, the Swiss industrial robotics leader, has gained 88.52% over the past year. Intuitive Surgical (NASDAQ:ISRG) just posted 22.96% revenue growth with da Vinci procedures up 16% and Ion procedures up 39%. Cognex (NASDAQ:CGNX), whose machine vision systems sit inside production-line robots, has risen 115.92% over the past year, driven by 24.26% revenue growth.

The diversification mechanism

The argument is the same one that pushes investors into a chip ETF rather than a single chipmaker. Whichever company eventually wins humanoid robots, the picks-and-shovels names (NVIDIA for compute, Cognex for vision, ABB and FANUC for industrial arms) get paid along the way. BOTZ captures that flow today rather than waiting on a single product launch.

The tradeoffs

For taxable accounts, selling Tesla after holding it for a long time would trigger capital gains. A partial swap, sizing BOTZ to the robotics conviction the reader actually has while keeping a residual Tesla position for the auto and Optimus optionality, may be more tax-efficient than a full exit.

What this changes for a Tesla holder

If the reason for owning Tesla is the car company plus full self-driving (FSD), with active subscriptions reaching 1.28 million, up 51% year over year, the position still makes sense on its own terms. If the reason is robotics specifically, paying 378 times earnings for zero current robotics revenue is a steep way to access a theme already represented in a diversified ETF. BOTZ is the cleaner expression of that thesis, with the tradeoff that the upside is spread across many names rather than concentrated in one.

The post Forget Betting Everything on Tesla’s Robot. This Fund Already Owns the Robotics Winners appeared first on 24/7 Wall St..